1 of 1
Story summary
- The Centers for Disease Control and Prevention vaccine advisory panel (CDC) ended hepatitis B vaccination at birth.
- Democratic-led states and medical organizations, including the American Academy of Pediatrics, plan to ignore guidance.
- The change disrupts decades of vaccination policy and could yield fragmented state-level responses.
- The birth-dose segment is valued between $50 million and $100 million annually.
- Experts warn the shift could create confusion and chaos in vaccination practices across the U.S.
